Printer Friendly

ATRIX LABORATORIES NAMES JOHN E. URHEIM AS VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER

 FORT COLLINS, Colo., June 16 /PRNewswire/ -- Atrix Laboratories Inc. (NASDAQ: ATRX) announced that John E. Urheim has joined the company as vice chairman and chief executive officer. Dr. G. Lee Southard will remain president of Atrix and chief scientific officer.
 Urheim has 28 years of experience in business development, product management and marketing within the healthcare and pharmaceutical industries. He has worked at companies such as Abbott Laboratories and G.D. Searle & Co. During his tenure as vice president at Searle, he was responsible for the launch of eight new products in the cardiovascular, pulmonary, anti-infective and contraceptive areas. Urheim oversaw the development of these products from clinical trials through FDA approval to commercialization. During his nine years at Abbott Laboratories, Urheim worked in the hospital products division. Urheim was president and chief executive officer from 1984 to 1989 at Gynex Pharmaceuticals Inc. Most recently, he headed Urheim Consulting where he has focused his efforts on mergers and helping companies form strategic alliances within the healthcare industry.
 John J. Horan, Atrix's chairman commented, "We are extremely pleased that John Urheim is joining the company. We view his extensive experience in the healthcare and pharmaceutical businesses as a tremendous asset to us. We believe that John will also help us to grow through structuring strategic alliances in order to develop a line of products based on our ATRIGEL(TM) drug delivery system."
 Southard stated, "I believe that our research efforts have placed Atrix on the verge of an important growth phase and John will effectively direct the company during this critical stage of our development. We are confident that he will assist us in attaining our goal of becoming a significant company in the drug delivery and periodontal disease treatment areas."
 Urheim said, "I am impressed with the people at Atrix and the technology base of the company. I am eager to assume my new position at Atrix and to be a part of the company's growth and success."
 Atrix Laboratories is a drug delivery company with a unique, patented, biodegradable drug delivery system that can be utilized for a broad range of drug delivery and medical device applications including periodontal disease treatment.
 -0- 6/16/93
 /CONTACT: Susan Sherman of Atrix Laboratories, 303-482-5868/
 (ATRX)


CO: Atrix Laboratories Inc. ST: Colorado IN: MTC SU: PER

BB -- DV001 -- 2528 06/16/93 10:17 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1993
Words:393
Previous Article:NEWCOR ANNOUNCES QUARTERLY DIVIDEND
Next Article:BERGEN BRUNSWIG REPORTS THIRD QUARTER AND NINE MONTHS RESULTS
Topics:


Related Articles
ATRIX LABORATORIES AND SYNTEX SIGN AGREEMENT
ATRIX LABORATORIES ANNOUNCES YEAR END RESULTS
ATRIX LABORATORIES REPORTS INTERIM RESULTS
ATRIX LABORATORIES ANNOUNCES POSITIVE STUDY RESULTS IN TREATING PERIODONTAL DISEASE
ATRIX LABORATORIES ANNOUNCES SECOND QUARTER RESULTS
ATRIX SIGNS LICENSE AGREEMENT WITH PARAVAX TO DEVELOP PERIODONTAL TREATMENT FOR COMPANION ANIMALS
ATRIX ANNOUNCES NEW V.P. OF DENTAL CLINICAL RESEARCH
ATRIX LABORATORIES COMPLETES PHASE III CLINICAL TRIALS
ATRIX LABORATORIES BUYS MANUFACTURING FACILITY
Atrix Laboratories Reports 1997 First Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters